Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?

MLA

Giovanna Piscopo, et al. Trastuzumab and Target-Therapy Side Effects: Is Still Valid to Differentiate Anthracycline Type I from Type II Cardiomyopathies? Jan. 2016. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8388b4680239786988fecb0d80285e37&authtype=sso&custid=ns315887.

APA

Giovanna Piscopo, Immacolata Capasso, Nicola Maurea, Claudia De Lorenzo, Emanuela Esposito, Carlo Maurea, Gennaro Riccio, & C. Coppola. (2016). Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?

Chicago

Giovanna Piscopo, Immacolata Capasso, Nicola Maurea, Claudia De Lorenzo, Emanuela Esposito, Carlo Maurea, Gennaro Riccio, and C. Coppola. 2016. “Trastuzumab and Target-Therapy Side Effects: Is Still Valid to Differentiate Anthracycline Type I from Type II Cardiomyopathies?,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8388b4680239786988fecb0d80285e37&authtype=sso&custid=ns315887.